Research Associate/Senior Research Associate, Nurix Adoptive Cell Therapy (NxACT)

San Francisco, CA, United States
Jul 21, 2021
Biotech Bay
Required Education
Bachelors Degree
Position Type
Full time
The Position

The successful candidate will be responsible for the execution of research activities toward the development of drug-enhanced cell-based therapies for Nurix's clinical development programs targeting protein fate for cancer targeted therapy and immunotherapy on its San Francisco campus. Collaborating with the Discovery (located on the San Francisco campus) and Process Development (located at the Pittsburgh campus) organizations, the RA/SRA will be responsible for executing preclinical studies, analysis, and interpretation of data to guide indication selection for early clinical development.

Job Responsibilities
  • Utilize broad technical expertise in cell and tumor immunology, biochemistry, and molecular biology to investigate, develop and optimize new methods to expand mechanistic understanding of Nurix's clinical development assets
  • Generate and characterize human drug enhanced tumor infiltrating lymphocytes (DeTIL) using advanced methods of T cell expansion and cell culture
  • Prioritize early small molecule drug candidates for their ability to enhance growth and focus of anti-tumor DeTIL as therapeutic reagents in combination with NxACT SF (DeTIL-03)
  • Establishing measures of successful DeTIL process outcomes by assessment of the infusion products, and by characterizing persistence (Phenotype, Nanostring, iRepertoire, scATACseq) to enable continuous process improvement
  • Assess and implement novel cell therapy strategy (DeTIL-02) that enables a more expeditious and effective cell product based on stem-like properties, a broadened repertoire, and expanded clones from human tumors

Education and Skills Requirements
  • For RA: Bachelor's or Master's degree. Industry experience is a plus.
  • For SRA: Master's degree in Biochemistry, Cell and Molecular Biology, or related field with 6+ years industry experience (or Bachelor's degree with 8+ years of industry experience).
  • Understanding of biology supporting adoptive cellular therapy as a therapeutic modality
  • Ideally, candidate will have training and/or experience in designing and implementing in vitro functional cell culture assays, including assessments of cytotoxicity, cytokine production and proliferative capacity in addition to the other measures noted above
  • Demonstrable experience in multi-color flow cytometry panel design and characterization of cellular subsets in human blood and tissue is strongly desired
  • Ability to troubleshoot and interpret complex data in an independent fashion
  • Prior role in multidisciplinary projects and teams with ability to integrate cross-functional information is an advantage
  • Excellent interpersonal, verbal and written communication skills, creative thinking, problem solving, flexibility and demonstrated ability to harness existing data sets to inform translational research are essential for this role
  • Collaborative spirit and ability to work with project teams, external investigators, and contract research organizations
  • Highly motivated, innovative, and strong team player. Excellent time management and organizational skills required.


Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix's extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.

Nurix's wholly owned pipeline comprises targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.